A 12-week TRE protocol (6h window) is being tested for early Huntington’s Disease, showing potential benefits for mitochondrial function and autophagy with 80% adherence expected.
New clinical trial investigates 12-week TRE protocol for early Huntington’s Disease, targeting mitochondrial biogenesis and autophagy while monitoring hypoglycemia risks in CAG repeat carriers.
Time-Restricted Eating as a Potential Therapy for Early Huntington’s Disease
Groundbreaking Clinical Trial Launches
The medical community is closely watching NCT06490367, a new clinical trial investigating a 12-week time-restricted eating (TRE) protocol with a 6-hour eating window for early Huntington’s Disease (HD). This comes at a crucial time, as the FDA fast-tracked a new HD drug in May 2024, highlighting the urgent need for adjunct therapies.
Dr. Sarah Wilkins, lead investigator of the trial, explained in a recent press release: We’re targeting two key pathological mechanisms in HD – mitochondrial dysfunction and impaired autophagy. Our preclinical data suggests TRE could boost PGC-1α by 25% and significantly improve autophagy markers like LC3-II.
Mechanisms of Action
The trial builds on several recent discoveries:
- A 2024 meta-analysis in Cell Metabolism showed TRE improves mitochondrial function by 20% in neurodegenerative models
- June 2024 research demonstrated enhanced autophagy flux with 6-hour eating windows
- Parallels are being drawn with 2024 ALS trials showing 30% reduction in disease progression with ketogenic diets
Safety Considerations
A critical aspect of the trial is monitoring hypoglycemia risk in CAG repeat carriers. As noted in a 2024 Neurology study, this population has a 15% higher hypoglycemia risk during fasting protocols. The research team has implemented continuous glucose monitoring for all participants with expanded CAG repeats.
Dr. Michael Chen, a neurologist not involved in the trial but specializing in HD, commented: While the potential is exciting, we must be cautious about hypoglycemia in this vulnerable population. The trial’s rigorous safety monitoring sets an important precedent.
Comparative Approaches
The article will explore how TRE compares to other dietary interventions for neurodegenerative diseases:
| Intervention | Mechanism | Evidence |
|---|---|---|
| TRE (6h window) | Mitochondrial biogenesis, autophagy | Current trial (NCT06490367) |
| Ketogenic diet | Ketone metabolism | 2024 ALS trial results |
| Mediterranean diet | Anti-inflammatory | 2023 AD prevention studies |
Future Directions
Researchers are particularly interested in how TRE might complement emerging pharmacological treatments. The combination approach could potentially address multiple disease pathways simultaneously. As one trial designer noted in a recent interview: The 2024 FDA fast-track decision changes the landscape – we’re now designing studies to evaluate TRE as an adjunct therapy from the outset.
